Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Thursday, November 11, 2021 1 min read

Key Takeaway: Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference

Full Press Release Details

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details